JANX is not a strong buy right now for a beginner long-term investor, even with a $50,000-$100,000 budget. The pre-market setup is constructive and the stock is near a key resistance area, but the overall picture is mixed: momentum is improving, yet analyst targets have been cut repeatedly, hedge funds are selling, and the company still lacks a clear near-term fundamental catalyst. If the investor is impatient and wants to act now, I would still rate it as HOLD rather than BUY.
MACD is positive and expanding, RSI is moderately elevated, and price is testing resistance around 14.752. This supports a short-term bounce setup but not a high-conviction long-term breakout.

Ongoing clinical work on JANX007, JANX014, and JANX011; low expectations after prior selloff; continued bullish long-term analyst coverage from several firms.
Repeated analyst target cuts, hedge fund selling, discontinued JANX008, delayed JANX007 data timeline, and no major positive news catalyst today.
Latest quarter details were not available in the provided snapshot.
Consensus remains mixed: bulls still like the platform, but the target cuts and downgrades show reduced confidence in near-term upside.